A Prescription Drug User Fee Act (PDUFA) target action date for apitegromab has been set for Sept. 22, 2025.

Sanofi (NASDAQ:SNY) said on Tuesday that the US FDA has granted priority review to the regulatory submission of tolebrutinib ...

The FDA approved Humacyte’s lab-grown blood vessel Symvess despite internal warnings from agency scientists about its safety ...

Fox News contributor Dr. Marty Makary was officially confirmed to lead the FDA in Trump's second administration after a vote ...

Test results from Consumer Reports found potentially harmful chemicals in roughly half of the formula products. “Eight of the ...

The Food and Drug Administration (FDA) announced a new initiative Tuesday titled “Operation Stork Speed” aimed at reviewing ...

Weight loss clinics, telehealth companies, physicians, and pharmacies that have been prescribing or dispensing compounded GLP ...

HHS Secretary Robert F. Kennedy Jr. discussed a new initiative aimed at improving the safety and nutritional value of baby ...